In silico pharmacology for drug discovery:: applications to targets and beyond

被引:245
作者
Ekins, S.
Mestres, J.
Testa, B.
机构
[1] ACT LLC, New York, NY 10119 USA
[2] Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA
[3] Inst Municipal Invest Med, Res Unit Biomed Informat, Chemogenom Lab, E-08003 Barcelona, Spain
[4] Univ Pompeu Fabra, Barcelona, Spain
[5] Univ Hosp Ctr, Lausanne, Switzerland
关键词
quantitative structure-activity relationships; homology models; docking; pharmacology; ADME/Tox; in silico; in vitro; drug discovery; computational;
D O I
10.1038/sj.bjp.0707306
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Computational (in silico) methods have been developed and widely applied to pharmacology hypothesis development and testing. These in silico methods include databases, quantitative structure-activity relationships, similarity searching, pharmacophores, homology models and other molecular modeling, machine learning, data mining, network analysis tools and data analysis tools that use a computer. Such methods have seen frequent use in the discovery and optimization of novel molecules with affinity to a target, the clarification of absorption, distribution, metabolism, excretion and toxicity properties as well as physicochemical characterization. The first part of this review discussed the methods that have been used for virtual ligand and target-based screening and profiling to predict biological activity. The aim of this second part of the review is to illustrate some of the varied applications of in silico methods for pharmacology in terms of the targets addressed. We will also discuss some of the advantages and disadvantages of in silico methods with respect to in vitro and in vivo methods for pharmacology research. Our conclusion is that the in silico pharmacology paradigm is ongoing and presents a rich array of opportunities that will assist in expediating the discovery of new targets, and ultimately lead to compounds with predicted biological activity for these novel targets.
引用
收藏
页码:21 / 37
页数:17
相关论文
共 170 条
[1]   A preliminary in silico lead series of 2-phthalimidinoglutaric acid analogues designed as MMP-3 inhibitors [J].
Amin, Elizabeth A. ;
Welsh, William J. .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2006, 46 (05) :2104-2109
[2]  
ARONOV AM, 2006, IN PRESS COMPUTATION
[3]  
Balakin Konstantin V, 2005, Curr Drug Discov Technol, V2, P99, DOI 10.2174/1570163054064666
[4]   Quantitative structure-metabolism relationship modeling of metabolic N-dealkylation reaction rates [J].
Balakin, KV ;
Ekins, S ;
Bugrim, A ;
Ivanenkov, YA ;
Korolev, D ;
Nikolsky, YV ;
Ivashchenko, AA ;
Savchuk, NP ;
Nikolskaya, T .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (10) :1111-1120
[5]   CRYSTAL-STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN-D - IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN [J].
BALDWIN, ET ;
BHAT, TN ;
GULNIK, S ;
HOSUR, MV ;
SOWDER, RC ;
CACHAU, RE ;
COLLINS, J ;
SILVA, AM ;
ERICKSON, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (14) :6796-6800
[6]   Pharmacophore modeling as an efficient tool in the discovery of novel noncompetitive AMPA receptor antagonists [J].
Barreca, ML ;
Gitto, R ;
Quartarone, S ;
De Luca, L ;
De Sarro, G ;
Chimirri, A .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2003, 43 (02) :651-655
[7]   An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression [J].
Becker, Oren M. ;
Dhanoa, Dale S. ;
Marantz, Yael ;
Chen, Dongli ;
Shacham, Sharon ;
Cheruku, Srinivasa ;
Heifetz, Alexander ;
Mohanty, Pradyumna ;
Fichman, Merav ;
Sharadendu, Anurag ;
Nudelman, Raphael ;
Kauffman, Michael ;
Noiman, Silvia .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (11) :3116-3135
[8]   Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus [J].
Bi, XN ;
Haque, TS ;
Zhou, J ;
Skillman, AG ;
Lin, B ;
Lee, CE ;
Kuntz, ID ;
Ellman, JA ;
Lynch, G .
JOURNAL OF NEUROCHEMISTRY, 2000, 74 (04) :1469-1477
[9]   Differential targeting of Gβγ-subunit signaling with small molecules [J].
Bonacci, TM ;
Mathews, JL ;
Yuan, CJ ;
Lehmann, DM ;
Malik, S ;
Wu, DQ ;
Font, JL ;
Bidlack, JM ;
Smrcka, AV .
SCIENCE, 2006, 312 (5772) :443-446
[10]   New serotonin 5-HT2A, 5-HT2B, and 5-HT2c receptor antagonists:: Synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones [J].
Brea, J ;
Rodrigo, J ;
Carrieri, A ;
Sanz, F ;
Cadavid, MI ;
Enguix, MJ ;
Villazón, M ;
Mengod, G ;
Caro, Y ;
Masaguer, CF ;
Raviña, E ;
Centeno, NB ;
Carotti, A ;
Loza, MI .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (01) :54-71